Why the study?
Dual antithrombotic therapy combining oral anticoagulation, preferentially NOAC, and single antiplatelet therapy is recommended after PCI in patients with an indication for OAC, prompting a nation-wide comparison of outcomes between VKA and NOAC-treated patients.
Does discharge on a NOAC compared to a VKA reduce 1-year major bleeding and major adverse cardiac events (all-cause mortality, MI, and ischemic stroke) in patients undergoing PCI with an indication for long-term oral anticoagulation?
Cohort (n=7,277)
Yes
Does discharge on a NOAC compared to a VKA reduce 1-year major bleeding and major adverse cardiac events (all-cause mortality, MI, and ischemic stroke) in patients undergoing PCI with an indication for long-term oral anticoagulation?
Answers are grounded in this paper and cite their sources.
In a large nationwide French PCI registry, discharging patients on a NOAC rather than a VKA was associated with lower 1-year rates of major bleeding, MACE, and mortality, although strong indication bias and residual confounding may partially explain the survival benefit.
Introduction Dual antithrombotic therapy (DAT) combining oral anticoagulation (OAC), preferentially Non-vitamin K antagonist OAC (NOAC) and single antiplatelet therapy (SAPT) for a period of 6–12 months is recommended after percutaneous coronary intervention (PCI) in patients with an indication for OAC. Objective To compare outcomes between vitamin K antagonist (VKA) and NOAC-treated patients in the nation-wide France PCI registry. Methods All consecutive patients from the France PCI registry treated by PCI and discharged with OAC between 2014 and 2020 were included and followed one-year. Major bleeding was defined as Bleeding Academic Research Consortium (BARC) classification ≥3 and major adverse cardiac events (MACE) as the composite of all-cause mortality, myocardial infarction (MI), and ischemic stroke. A propensity-score analysis was used. Results Of the 7,277 eligible participants, 2,432 (33.4%) were discharged on VKA and 4,845 (66.6%) on NOAC. After propensity-score adjustment, one-year major bleeding was less frequent in NOAC vs. VKA-treated participants [3.1% vs. 5.2%, −2.1% (−3.6% to −0.6%), p = 0.005 as well as the rate of MACE [9.2% vs. 11.9%, −2.7% (−5.0% to −0.4%), p = 0.02]. One-year mortality was also significantly decreased in NOAC vs. VKA-treated participants [7.4% vs. 9.9%, −2.6% (−4.7% to −0.5%), p = 0.02]. The area under ROC curves of the anticoagulant treatment propensity score was estimated at 0.93, suggesting potential indication bias Conclusions NOAC seems to have a better efficacy and safety profile than VKA. However, potential indication bias were found.
No takes yet. Share an insight, caveat, or question.
Durand et al. (2024) conducted a cohort in Patients undergoing percutaneous coronary intervention (PCI) with an indication for long-term oral anticoagulation (OAC) (n=7,277). Non-vitamin K antagonist oral anticoagulant (NOAC) at hospital discharge (apixaban, rivaroxaban, or dabigatran) vs. Vitamin K antagonist (VKA) at hospital discharge was evaluated on Major bleeding (BARC classification ≥3) at 1 year (co-primary with MACE: composite of all-cause mortality, MI, and ischemic stroke) (ARR -2.1%, 95% CI -3.6% to -0.6%, p=0.005).
Synapse has enriched 10 related papers. Consider them for comparative context: